Riskpilot← Back to searchSign inGet full accessStemedicus AB
ABActiveOrg 5566127071Odengatan 29Research and experimental development on natural sciences and engineering · NACE 7210Est. 20010 employees
Revenue 2024
SEK 6K
EBITDA margin
33.3%
+150% vs 2023
Equity ratio
84.6%
Financial strength
Net profit 2024
SEK 10K
+400% vs 2023
| Revenue | SEK 6K | — |
| EBITDA | SEK 2K | +150% |
| Net profit | SEK 10K | +400% |
| Total assets | SEK 389K | +3% |
| Equity | SEK 329K | +3% |
| Employees | 0 | — |
Legal name
Stemedicus AB
Org number
5566127071
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25 juli 2001
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva medicinsk utveckling och forskning samt konsultation inom hälso- och sjukvård. Äga och förvalta värdepapper och handel med aktier och jämförbara värdepapper samt konstföremål och fast egendom.
Address
Odengatan 29
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 17 | 38 | 0 | 4 | 0 | 0 | 0 | 6 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 15 | −2 | −5 | 17 | −25 | −5 | −6 | −20 | −4 | 2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −3 | −0 | −0 | −0 |
| EBIT | 15 | −2 | −5 | 17 | −25 | −5 | −9 | −20 | −4 | 2 |
| Net financials | — | 2 | — | 2 | 1 | 1 | 1 | 1 | 6 | 7 |
| Profit before tax | 41 | 19 | −5 | 19 | −24 | −4 | −8 | −19 | 2 | 10 |
| Tax | −9 | −4 | −0 | −4 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 32 | 15 | −5 | 15 | −24 | −4 | −8 | −19 | 2 | 10 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 402 | 402 | 397 | 417 | 396 | 388 | 391 | 378 | 379 | 389 |
| Equity | 347 | 362 | 357 | 372 | 348 | 344 | 336 | 318 | 320 | 329 |
| Long-term debt | 21 | 25 | 28 | 31 | 36 | 39 | 52 | 57 | 57 | 57 |
| Short-term debt | 14 | 15 | 13 | 14 | 12 | 4 | 3 | 3 | 2 | 2 |
| Total debt | 35 | 40 | 41 | 45 | 48 | 43 | 55 | 60 | 59 | 59 |
EBITDA margin
33.3%
This company
15.8%
Market median
+111% vs market
20152024
Equity ratio
84.6%
This company
38.2%
Market median
+121% vs market
20152024
Return on equity
3.0%
This company
18.4%
Market median
-84% vs market
20152024
Net profit margin
166.7%
This company
8.1%
Market median
+1958% vs market
20152024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20152024
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AG | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Stemedicus AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Gabriel Lundgren | Audit | 0 companies |
| Rolf Hans Lassas Stenke | Deputy Board Member | 0 companies |
| Leif Åke Lassas Stenke | Board of Directors | 0 companies |